1431541-38-6

Basic information

• Product Name: {3-[6-(5-methyl-6-methylamino-pyridin-3-yl)-quinazolin-4-yl]-phenyl}-(4-methyl-piperazin-1-yl)-methanone
• Synonyms: {3-[6-(5-methyl-6-methylamino-pyridin-3-yl)-quinazolin-4-yl]-phenyl}-(4-methyl-piperazin-1-yl)-methanone
• CAS NO: 1431541-38-6
• Molecular Weight: 452.559
• Mol File: 1431541-38-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: {3-[6-(5-methyl-6-methylamino-pyridin-3-yl)-quinazolin-4-yl]-phenyl}-(4-methyl-piperazin-1-yl)-methanone(CAS DataBase Reference)
• NIST Chemistry Reference: {3-[6-(5-methyl-6-methylamino-pyridin-3-yl)-quinazolin-4-yl]-phenyl}-(4-methyl-piperazin-1-yl)-methanone(1431541-38-6)
• EPA Substance Registry System: {3-[6-(5-methyl-6-methylamino-pyridin-3-yl)-quinazolin-4-yl]-phenyl}-(4-methyl-piperazin-1-yl)-methanone(1431541-38-6)

Safety Data

• Hazardous Substances Data: 1431541-38-6(Hazardous Substances Data)

Upstream product

• 1431542-30-1 [3-(6-bromo-quinazolin-4-yl)-phenyl]-(4-methyl-piperazin-1-yl)-methanone 
• 1032758-82-9 methyl-[3-methyl-5-(4,4_,5,5-tetramethyl-[1,3,2]dioxaborolan-2yl)-pyridin-2-yl]-carbamic acid tert-butylester 
• 32084-59-6 6-bromoquinazolin-4(3H)-one 
• 38267-96-8 6-bromo-4-chloroquinozoline 
• 4334-87-6 [3-(ethoxycarbonyl)phenyl]boronic acid 
• 1431542-29-8 3-(6-bromo-quinazolin-4-yl)-benzoic acid ethyl ester 
• 1431542-28-7 3-(6-bromo-quinazolin-4-yl)-benzoic acid 

Relevant articles and documents

Use of Inhibitors of the Activity or Function of PI3K

The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.

Use of inhibitors of the activity or function of PI3K

The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.